Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.

Current cancer drug targets - 1 Sept 2012

Joyce T, Oikonomou E, Kosmidou V, Makrodouli E, Bantounas I, Avlonitis S, Zografos G, Pintzas A

Abstract excerpt

Sporadic colorectal cancer develops through a number of functional mutations. Key events are mutually exclusive mutations in BRAF or RAS oncogenes. Signatures for BRAF oncogene have been revealed in melanoma. In a previous study we have reported a molecular signature for HRAS and KRAS mutations in colorectal cell lines that also showed an EMT phenotype for HRAS. In this study we report a molecular profile for a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caco-2 Cells
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to HEK293 Cells

Share to Microarray Analysis

Share to Oncogenes

Share to Proto-Oncogene Proteins B-raf

Share to Up-Regulation

Source

Identifiers

PMID: 22515520
DOI: 10.2174/156800912802429364

Genes

BRAF
HRAS
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.PMID 22515520Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

Development of an accessible gene expression bioinformatics pipeline to study driver mutations of colorectal cancerSemantic proximity Read ↗

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Semantic proximity Read ↗

Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer.Semantic proximity Read ↗

New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.Semantic proximity Read ↗

BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.Semantic proximity Read ↗

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.Semantic proximity Read ↗

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.Semantic proximity Read ↗

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancer: An UpdateSemantic proximity Read ↗

B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.